Table 1 Baseline demographics and clinicopathological characteristics
Variables | All patients (N = 113) | |
|---|---|---|
Category | Total (%) | |
Age | Mean ± SD, years | 56.8 ± 11.5 |
< 60 | 67 (59.3) | |
≥ 60 | 46 (40.7) | |
Sex | ||
Male | 51 (45.1) | |
Female | 62 (54.9) | |
Smoking status | ||
Never smoker | 98 (86.7) | |
Ever/current smoker | 15 (13.3) | |
Main complaint | ||
Cough with or without blood-tinged sputum | 29 (25.7) | |
Hemoptysis | 4 (3.5) | |
Chest pain | 4 (3.5) | |
Asymptomatic | 76 (67.3) | |
AJCC 8th stage | ||
I | 43 (38.1) | |
II | 19 (16.8) | |
III | 36 (31.9) | |
IV | 15 (13.3) | |
T stage | ||
T1 | 27 (23.9) | |
T2 | 53 (46.9) | |
T3 | 16 (14.2) | |
T4 | 17 (15.0) | |
N stage | ||
N0 | 62 (54.9) | |
N1 | 7 (6.2) | |
N2 | 26 (23.0) | |
N3 | 18 (15.9) | |
M stage | ||
M0 | 98 (86.7) | |
M1 | 15 (13.3) | |
CYFRA21-1 | ||
Normal | 71 (62.8) | |
Elevated | 42 (37.2) | |
EGFR (n = 57) # | ||
Mutated | 0 (0) | |
Wild | 57 (100) | |
ALK (n = 45) # | ||
Mutated | 0 (0) | |
Wild | 45 (100) | |
KRAS (n = 40) # | ||
Mutated | 0 (0) | |
Wild | 40 (100) | |
Treatment procedure | ||
Surgery alone | 48 (42.5) | |
Surgery and adjuvant therapy* | 37 (32.7) | |
Other therapy† | 28 (24.8) | |
EBER in situ hybridization (N = 83)# | ||
Negative | 3 (3.6) | |
Positive | 80 (96.4) | |
Recurrence | ||
Local | 22 (19.5) | |
Regional | 8 (7.1) | |
Distant metastasis | 8 (7.1) | |
Death | ||
Cancer specific deaths | 20 (17.7) | |
Treatment related mortality | 1 (0.9) | |